[ad_1]
For the first time, the state organizes the opening of tenders for the centralized procurement of high-value medical consumables.
The average purchase price of centralized coronary stents fell from 10,000 yuan to less than 1,000 yuan.
On the 5th, China’s first round of centralized procurement of high-value medical consumables organized by the state officially opened in Tianjin. 10 products are planned to be selected from 8 companies, including Esen Technology, Shanghai MicroPort Medical and Lepu Medical. The price of coronary stents The average price will drop from the previous 13,000 yuan to about 700 yuan.
Relevant people from the National Medical Insurance Office stated that the national coronary stent centralized procurement organization has adhered to the successful experience of centralized drug procurement. For example, adhere to the integration of contracting and acquisition, link volume and price, clarify the target volume, and provide selected companies with stable market expectations. Products no longer need to be marketed for clinical use, compress circulating moisture, and promote prices to return to a reasonable level; insist on the voluntary participation of companies, independent quotes, fair competition and give full play to the role of market mechanisms.
The above-mentioned people said that the state-organized centralized procurement of coronary stents is an important measure to control the price of high-value medical consumables and circulation chaos, and is also a key part of comprehensively deepening the reform of centralized procurement in the medical field. The substantial reduction in purchase prices will significantly reduce the burden of medical expenses for the masses. Patients across the country are expected to use the selected products after the national centralized acquisition price reduction in January 2021.
Specifically, a total of 11 companies participated in the tender this time, and 26 registered and listed coronary stent products in China participated. Through the competition, 10 products were selected, belonging to Shandong Jiwei Medical Products Co., Ltd., Esun Technology (Beijing) Co., Ltd., Shanghai MicroPort Medical Equipment (Group) Co., Ltd. and Lepu ( Beijing) Medical Equipment Co., Ltd., Medtronic (Shanghai) Management Co., Ltd. and 8 other companies.
Judging by the specific circumstances of the offer, the main products commonly used clinically by medical institutions are basically selected, covering more than 70% of the purchases planned by medical institutions. Compared to 2019, the average price of the same products from the same company has decreased by 93%, the average price of domestic products has decreased by 92%, and the price of imported products has decreased by 95% average. Based on the amount of planned purchases, it is expected to save 10.9 billion yuan.
“Currently, the national market share for private label cardiac stents is almost 70%. After this purchase, this share can be further expanded.” Some experts said that under national procurement, this round of centralized procurement is better than previous local pilot consumables. The fall in the price of volume purchases is even more pronounced, companies exchange price for volume and domestic substitution has increased even more.
The aforementioned industry experts said that with the normalization of volume purchases, the sales of related companies will increase significantly, but sales expenses will be significantly reduced, and the volume price advantage will gradually become prominent. Previously, Huahai Pharmaceutical, the company that won the bid for the centralized procurement of pharmaceuticals, said that the increase in the company’s net profit in the first half of this year was the main reason for the decrease in selling expenses. The rapid increase has affected the sales of domestic preparations to increase substantially. (Reporter Liang Qian)
